Literature DB >> 8262217

A role for central A3-adenosine receptors. Mediation of behavioral depressant effects.

K A Jacobson1, O Nikodijević, D Shi, C Gallo-Rodriguez, M E Olah, G L Stiles, J W Daly.   

Abstract

The behavioral effects of a selective A3 adenosine receptor agonist 3-IB-MECA (N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine) in mice and the localization of radioligand binding sites in mouse brain were examined. Low levels of A3 adenosine receptors were detected in various regions of the mouse brain (hippocampus, cortex, cerebellum, striatum), using a radioiodinated, high-affinity A3-agonist radioligand [125I]AB-MECA (N6-(3-iodo-4-aminobenzyl)-5'-N-methylcarboxamidoadenosine). Scatchard analysis in the cerebellum showed that the Kd value for binding to A3 receptors was 1.39 +/- 0.04 nM with a Bmax of 14.8 +/- 2.1 fmol/mg protein. 3-IB-MECA at 0.1 mg/kg i.p. was a locomotor depressant with > 50% reduction in activity. Although selective A1 or A2a antagonists reversed locomotor depression elicited by selective A1 or A2a agonists, respectively, the behavioral depressant effects of 3-IB-MECA were unaffected. 3-IB-MECA also caused scratching in mice, which was prevented by coadministration of the histamine antagonist cyproheptadine. The demonstration of a marked behavioral effect of A3 receptor activation suggests that the A3 receptor represents a potential new therapeutic target.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262217      PMCID: PMC4287251          DOI: 10.1016/0014-5793(93)81608-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.

Authors:  C Gallo-Rodriguez; X D Ji; N Melman; B D Siegman; L H Sanders; J Orlina; B Fischer; Q Pu; M E Olah; P J van Galen
Journal:  J Med Chem       Date:  1994-03-04       Impact factor: 7.446

2.  125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.

Authors:  M E Olah; C Gallo-Rodriguez; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1994-05       Impact factor: 4.436

3.  Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism.

Authors:  O Nikodijević; R Sarges; J W Daly; K A Jacobson
Journal:  J Pharmacol Exp Ther       Date:  1991-10       Impact factor: 4.030

4.  Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor.

Authors:  H Ali; J R Cunha-Melo; W F Saul; M A Beaven
Journal:  J Biol Chem       Date:  1990-01-15       Impact factor: 5.157

5.  Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus.

Authors:  D K von Lubitz; J M Dambrosia; O Kempski; D J Redmond
Journal:  Stroke       Date:  1988-09       Impact factor: 7.914

6.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Effects of chronic administration of adenosine A1 receptor agonist and antagonist on spatial learning and memory.

Authors:  D K Von Lubitz; I A Paul; R T Bartus; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1993-11-16       Impact factor: 4.432

8.  Adenosine receptors and behavioral actions of methylxanthines.

Authors:  S H Snyder; J J Katims; Z Annau; R F Bruns; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

Review 9.  Adenosine A1 and A2 receptors: structure--function relationships.

Authors:  P J van Galen; G L Stiles; G Michaels; K A Jacobson
Journal:  Med Res Rev       Date:  1992-09       Impact factor: 12.944

10.  8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo.

Authors:  K A Jacobson; O Nikodijević; W L Padgett; C Gallo-Rodriguez; M Maillard; J W Daly
Journal:  FEBS Lett       Date:  1993-05-24       Impact factor: 4.124

View more
  40 in total

1.  Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.

Authors:  S Merighi; K Varani; S Gessi; E Cattabriga; V Iannotta; C Ulouglu; E Leung; P A Borea
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells.

Authors:  B C Suh; T D Kim; J U Lee; J K Seong; K T Kim
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

3.  A(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse.

Authors:  M Y Avila; R A Stone; M M Civan
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

4.  A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.

Authors:  M L Trincavelli; D Tuscano; M Marroni; A Falleni; V Gremigni; S Ceruti; M P Abbracchio; K A Jacobson; F Cattabeni; C Martini
Journal:  Mol Pharmacol       Date:  2002-12       Impact factor: 4.436

5.  Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway.

Authors:  Mahmoud Aghaei; Mojtaba Panjehpour; Fatemeh Karami-Tehrani; Siamak Salami
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-10       Impact factor: 4.553

6.  Chapter 13. A3 Adenosine Receptors.

Authors:  Kenneth A Jacobson; Susanna Tchilibon; Bhalchandra V Joshi; Zhan-Guo Gao
Journal:  Annu Rep Med Chem       Date:  2003       Impact factor: 1.059

Review 7.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 8.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

9.  Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives.

Authors:  H O Kim; X D Ji; N Melman; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1994-11-11       Impact factor: 7.446

10.  Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO.

Authors:  P Nieri; E Martinotti; V Calderone; M C Breschi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.